Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains purified, inactivated viral antigens from specific influenza strains. After injection, antigen‑presenting cells process these proteins and present them to T‑cells, initiating a coordinated immune response. This leads to the production of strain‑specific antibodies that can neutralise the virus, preventing it from infecting cells if the person is later exposed.

The exact dose and schedule are determined by the prescribing healthcare professional. Typically, a single intramuscular or subcutaneous dose is given each influenza season, with specific recommendations for age groups and prior vaccination history. The prescriber will decide the appropriate volume and site of administration.

Influvac is an inactivated vaccine and is generally considered safe for use during pregnancy and lactation when the benefits outweigh potential risks. Pregnant or breastfeeding individuals should discuss vaccination with their obstetrician or healthcare provider to ensure timing aligns with current clinical guidelines.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Influvac. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain logistics if needed—and necessary import documentation.

Influvac is an inactivated, split‑virus vaccine targeting the same influenza A (Victoria) and B (Austria) strains as many other seasonal vaccines. Compared with live‑attenuated nasal sprays, Influvac is administered by injection and is suitable for a broader range of age groups, including those with certain immunocompromising conditions. Efficacy and safety profiles are comparable to other licensed inactivated influenza vaccines.

Influvac must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging to protect from light, and must never be frozen or shaken. Prior to use, allow the vial to reach room temperature for a short period if required, and inspect for any discoloration or particulate matter before administration.

Influvac is given by a single intramuscular or subcutaneous injection, usually into the deltoid muscle of the upper arm or the anterolateral thigh in younger children. The injection is performed by a qualified healthcare professional using aseptic technique, and the site should be observed for any immediate reactions.

While rare, serious adverse events can include anaphylaxis, Guillain‑Barré syndrome, and seizures, particularly in children who develop a high fever. Recipients should be monitored for a short period after vaccination, and any signs of severe allergic reaction—such as difficulty breathing, swelling of the face or throat, or rapid pulse—require immediate medical attention.

Individuals with a known severe allergy to egg proteins or any component of the vaccine should avoid Influvac. Those who have experienced a previous severe reaction to any influenza vaccine should also be excluded. Additionally, persons with acute moderate or severe illness should defer vaccination until recovery.